论文信息 - Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125] - 字舞流文

Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]

T. Choueiri | M. Michaelson | T. Olencki | M. Morris | E. Small | D. Feldman | S. Dakhil | J. Picus | D. George | C. Hessel | S. Halabi | C. Scheffold | B. Sanford | M. Mangeshkar | O. Hahn | Meghara Walsh